Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017808540> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2017808540 endingPage "118" @default.
- W2017808540 startingPage "112" @default.
- W2017808540 abstract "Significant progress was achieved in the search of a thrombin receptor antagonist as a novel antithrombotic treatment since the thrombin receptor (protease-activated receptor-1, PAR-1) was cloned 20 years ago. Previous works have shown that it is possible to develop potent thrombin receptor antagonists to compete effectively with the receptor’s internal “tethered” ligand to block platelet activation. Vorapaxar (SCH 530348) from Schering-Plough (now Merck) and atopaxar (E5555) from Eisai have been advanced to human clinical trials. Recently, the pivotal phase III clinical trial results for vorapaxar were published. In this article we review these results plus the phase II results from atopaxar. Several newly described thrombin receptor antagonists from the literature will also be discussed. The phase III results from vorapaxar demonstrated that a thrombin receptor antagonist can achieve efficacy in addition to current standard- of-care in treating atherothrombotic patients, especially those with previous myocardial infarction (MI). However, the increased moderate and severe bleeding, especially intracranial bleeding, point to the limitations of current thrombin receptor antagonists. Future thrombin receptor antagonists that can improve on the efficacy and bleeding profile of current ones should have a promising place in meeting the unmet medical need in treating atherothrombotic patients using current standard therapy." @default.
- W2017808540 created "2016-06-24" @default.
- W2017808540 creator A5006818966 @default.
- W2017808540 creator A5080564743 @default.
- W2017808540 creator A5080751883 @default.
- W2017808540 creator A5085996982 @default.
- W2017808540 date "2012-01-01" @default.
- W2017808540 modified "2023-10-16" @default.
- W2017808540 title "Recent Development in Thrombin Receptor Antagonist as Novel Antithrombotic Agent" @default.
- W2017808540 cites W1525921618 @default.
- W2017808540 cites W1566543831 @default.
- W2017808540 cites W1990381860 @default.
- W2017808540 cites W2003965226 @default.
- W2017808540 cites W2035315991 @default.
- W2017808540 cites W2042990306 @default.
- W2017808540 cites W2058252463 @default.
- W2017808540 cites W2067676945 @default.
- W2017808540 cites W2072884900 @default.
- W2017808540 cites W2081753893 @default.
- W2017808540 cites W2085302164 @default.
- W2017808540 cites W2087180312 @default.
- W2017808540 cites W2106461531 @default.
- W2017808540 cites W2123673539 @default.
- W2017808540 cites W2134322421 @default.
- W2017808540 cites W2142021807 @default.
- W2017808540 cites W2142541327 @default.
- W2017808540 cites W2152813238 @default.
- W2017808540 cites W2156725039 @default.
- W2017808540 cites W2158910198 @default.
- W2017808540 cites W2165614730 @default.
- W2017808540 cites W2915398081 @default.
- W2017808540 cites W187268731 @default.
- W2017808540 doi "https://doi.org/10.4236/ojmc.2012.24014" @default.
- W2017808540 hasPublicationYear "2012" @default.
- W2017808540 type Work @default.
- W2017808540 sameAs 2017808540 @default.
- W2017808540 citedByCount "1" @default.
- W2017808540 countsByYear W20178085402016 @default.
- W2017808540 crossrefType "journal-article" @default.
- W2017808540 hasAuthorship W2017808540A5006818966 @default.
- W2017808540 hasAuthorship W2017808540A5080564743 @default.
- W2017808540 hasAuthorship W2017808540A5080751883 @default.
- W2017808540 hasAuthorship W2017808540A5085996982 @default.
- W2017808540 hasBestOaLocation W20178085401 @default.
- W2017808540 hasConcept C126322002 @default.
- W2017808540 hasConcept C149577978 @default.
- W2017808540 hasConcept C170493617 @default.
- W2017808540 hasConcept C2776885963 @default.
- W2017808540 hasConcept C2777015399 @default.
- W2017808540 hasConcept C2777292125 @default.
- W2017808540 hasConcept C2778122271 @default.
- W2017808540 hasConcept C2778886182 @default.
- W2017808540 hasConcept C57002609 @default.
- W2017808540 hasConcept C71924100 @default.
- W2017808540 hasConcept C89560881 @default.
- W2017808540 hasConcept C98274493 @default.
- W2017808540 hasConceptScore W2017808540C126322002 @default.
- W2017808540 hasConceptScore W2017808540C149577978 @default.
- W2017808540 hasConceptScore W2017808540C170493617 @default.
- W2017808540 hasConceptScore W2017808540C2776885963 @default.
- W2017808540 hasConceptScore W2017808540C2777015399 @default.
- W2017808540 hasConceptScore W2017808540C2777292125 @default.
- W2017808540 hasConceptScore W2017808540C2778122271 @default.
- W2017808540 hasConceptScore W2017808540C2778886182 @default.
- W2017808540 hasConceptScore W2017808540C57002609 @default.
- W2017808540 hasConceptScore W2017808540C71924100 @default.
- W2017808540 hasConceptScore W2017808540C89560881 @default.
- W2017808540 hasConceptScore W2017808540C98274493 @default.
- W2017808540 hasIssue "04" @default.
- W2017808540 hasLocation W20178085401 @default.
- W2017808540 hasOpenAccess W2017808540 @default.
- W2017808540 hasPrimaryLocation W20178085401 @default.
- W2017808540 hasRelatedWork W2017808540 @default.
- W2017808540 hasRelatedWork W2035602567 @default.
- W2017808540 hasRelatedWork W2037076708 @default.
- W2017808540 hasRelatedWork W2037637243 @default.
- W2017808540 hasRelatedWork W2042990306 @default.
- W2017808540 hasRelatedWork W2096686021 @default.
- W2017808540 hasRelatedWork W2115629785 @default.
- W2017808540 hasRelatedWork W2381853760 @default.
- W2017808540 hasRelatedWork W2414484722 @default.
- W2017808540 hasRelatedWork W2414570195 @default.
- W2017808540 hasVolume "02" @default.
- W2017808540 isParatext "false" @default.
- W2017808540 isRetracted "false" @default.
- W2017808540 magId "2017808540" @default.
- W2017808540 workType "article" @default.